OncClubAll Oncology NewsPipeline Report
InsightsMedical World NewsOncChatsOncLive News Network®OncLive TVPeer ExchangePodcastsRapid ReadoutsThe Talk
Conference CoverageConference Listing
Giants of Cancer CarePER EventsScientific InterchangesState of the Science Summit / IPCWebinars
Partners
Oncology Live®Oncology FellowsSupplements And Featured PublicationsAll Publications
CME/CE
Biomarker ConsortiumInteractive ToolsLearning ModulesPresentationsSponsored
Print SubscriptioneNewsletter
Biosimilars
Brain Cancer
Breast CancerBreast Cancer
Business Management
CAR T-cell Therapy
COVID-19
Disparities in Cancer Care
Gastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary Cancers
Global Oncology
Gynecologic OncologyGynecologic Oncology
Head & Neck Cancers
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
Immuno-OncologyImmuno-OncologyImmuno-OncologyImmuno-Oncology
Lung Cancer
Melanoma & Skin Cancer
Oncology Nursing News
Pediatric Oncology
Precision Medicine in Oncology®Precision Medicine in Oncology®
Sarcomas/TGCT
Supportive Care
Spotlight -
  • REGISTER TODAY to explore data on a novel second-generation BTK inhibitor for adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
  • Share your views with OncChats
Biosimilars
Brain Cancer
Breast CancerBreast Cancer
Business Management
CAR T-cell Therapy
COVID-19
Disparities in Cancer Care
Gastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary Cancers
Global Oncology
Gynecologic OncologyGynecologic Oncology
Head & Neck Cancers
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
Immuno-OncologyImmuno-OncologyImmuno-OncologyImmuno-Oncology
Lung Cancer
Melanoma & Skin Cancer
Oncology Nursing News
Pediatric Oncology
Precision Medicine in Oncology®Precision Medicine in Oncology®
Sarcomas/TGCT
Supportive Care
    • Partners
    • CME/CE
Advertisement

Ross Reflects on Surgical Advances and Changing Trends in CRC

March 10, 2022
OncLive Staff
Podcast

Dr Ross shares his advice to health care professionals regarding the detection and treatment of patients with colon cancer, unmet needs for this patient population, the role of minimally invasive surgery, and the need to address and overcome health disparities that affect this population.

Welcome to OncLive On Air®! I’m your host today, Jessica Hergert.

OncLive On Air® is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive® covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.

In today’s episode, we had the pleasure of speaking with Howard M. Ross, MD, a colon and rectal surgeon, chair of surgery, and surgeon in chief at Hackensack University Medical Center, and a professor and chair of the Department of Surgery at Hackensack Meridian School of Medicine, to discuss developments in the management of colon cancer in light of March being Colorectal Cancer Awareness month.

During our exclusive interview, Ross shared his advice to health care professionals regarding the detection and treatment of patients with colon cancer, unmet needs for this patient population, the role of minimally invasive surgery, and the need to address and overcome health disparities that affect this population.

Check back on Thursdays for exclusive interviews with leading experts in the oncology field. For more updates in oncology, be sure to visit www.OncLive.com and sign up for our e-newsletters.

OncLive® is also on social media. On Twitter, follow us at @OncLive and @OncLiveSOSS. On Facebook, like us at OncLive and OncLive State of the Science Summit and follow our OncLive page on LinkedIn.

If you liked today’s episode of OncLive On Air®, please consider subscribing to our podcast on Apple Podcasts, Spotify, Google Podcasts, Amazon Music, and many of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us!

Thanks again for listening to OncLive On Air®.

*OncLive On Air® is available on: Apple Podcasts, Google Podcasts, Spotify, Amazon Music, Audacy, CastBox, Deezer, iHeart, JioSaavn, Listen Notes, Player FM, Podcast Addict, Podchaser, RadioPublic, and TuneIn.

Related Videos
Jeremy C. Jones, MD
Marwan G. Fakih, MD
Howard S. Hochster, MD
Daneng Li, MD
Arvind Dasari, MD, MS, an expert on colorectal cancer
Megan Hitchins, PhD
Marwan G. Fakih, MD
Scott Kopetz, MD, PhD, FACP
Isabelle Franklin
Isabelle Franklin
Related Content

Japanese Approval Sought for Fruquintinib in Previously Treated Metastatic Colorectal Cancer

October 2nd 2023

Richardson Reviews Findings and Future Directions With Mezigdomide Plus Dexamethasone in R/R Myeloma

October 2nd 2023

IDEA Collaboration Affects Choice of Chemotherapy Regimen, Treatment Duration in Stage III Colon Cancer

September 18th 2023

Garcia-Manero and Zeidan Highlight Key Implications of the COMMANDS Trial in Lower-Risk MDS

September 28th 2023

FDA Grants Breakthrough Therapy Designations to Trastuzumab Deruxtecan for HER2+ Solid Tumors, Including mCRC

August 31st 2023

Trifluridine/Tipiracil Plus Bevacizumab Provides Potential First-Line Alternative to Bevacizumab/Capecitabine in mCRC

August 30th 2023

Japanese Approval Sought for Fruquintinib in Previously Treated Metastatic Colorectal Cancer

October 2nd 2023

Richardson Reviews Findings and Future Directions With Mezigdomide Plus Dexamethasone in R/R Myeloma

October 2nd 2023

IDEA Collaboration Affects Choice of Chemotherapy Regimen, Treatment Duration in Stage III Colon Cancer

September 18th 2023

Garcia-Manero and Zeidan Highlight Key Implications of the COMMANDS Trial in Lower-Risk MDS

September 28th 2023

FDA Grants Breakthrough Therapy Designations to Trastuzumab Deruxtecan for HER2+ Solid Tumors, Including mCRC

August 31st 2023

Trifluridine/Tipiracil Plus Bevacizumab Provides Potential First-Line Alternative to Bevacizumab/Capecitabine in mCRC

August 30th 2023

Japanese Approval Sought for Fruquintinib in Previously Treated Metastatic Colorectal Cancer

October 2nd 2023

Richardson Reviews Findings and Future Directions With Mezigdomide Plus Dexamethasone in R/R Myeloma

October 2nd 2023

IDEA Collaboration Affects Choice of Chemotherapy Regimen, Treatment Duration in Stage III Colon Cancer

September 18th 2023

Garcia-Manero and Zeidan Highlight Key Implications of the COMMANDS Trial in Lower-Risk MDS

September 28th 2023

FDA Grants Breakthrough Therapy Designations to Trastuzumab Deruxtecan for HER2+ Solid Tumors, Including mCRC

August 31st 2023

Trifluridine/Tipiracil Plus Bevacizumab Provides Potential First-Line Alternative to Bevacizumab/Capecitabine in mCRC

August 30th 2023
Related Content
Advertisement
Colorectal Cancer ©  stock.adobe.com

Japanese Approval Sought for Fruquintinib in Previously Treated Metastatic Colorectal Cancer

October 2nd 2023
Article
Paul G. Richardson, MD

Richardson Reviews Findings and Future Directions With Mezigdomide Plus Dexamethasone in R/R Myeloma

October 2nd 2023
Podcast
Daniel H. Ahn, DO

IDEA Collaboration Affects Choice of Chemotherapy Regimen, Treatment Duration in Stage III Colon Cancer

September 18th 2023
Article
Guillermo Garcia-Manero, MD; Amer Zeidan, MBBS, MHS

Garcia-Manero and Zeidan Highlight Key Implications of the COMMANDS Trial in Lower-Risk MDS

September 28th 2023
Podcast
FDA Grants Breakthrough Therapy Designations to Trastuzumab Deruxtecan for HER2+ Solid Tumors, Including mCRC

FDA Grants Breakthrough Therapy Designations to Trastuzumab Deruxtecan for HER2+ Solid Tumors, Including mCRC

August 31st 2023
Article
Thierry André, MD

Trifluridine/Tipiracil Plus Bevacizumab Provides Potential First-Line Alternative to Bevacizumab/Capecitabine in mCRC

August 30th 2023
Article

Latest Conference Coverage

Dr Deek on the Investigation of Immune Cell Infiltration in MIBC

Hypofractionated and Conventionally Fractionated Radiotherapy Generate Similar QOL, Safety in Breast Cancer

Dr Hoppe on the Rationale for the CheckMate 744 Trial in Hodgkin Lymphoma

Dr Chuong on the Patterns of Guided Radiation Therapy in Pancreatic Cancer

View More Latest Conference Coverage
Advertise
About OncLive
Editorial Board
CancerNetwork.com
CGTlive.com
CureToday.com
OncNursingNews.com
TargetedOnc.com
Contact Us
Privacy
Terms & Conditions
Do Not Sell My Information
Contact Info

2 Clarke Drive
Cranbury, NJ 08512

609-716-7777

© 2023 MJH Life Sciences

All rights reserved.
Home
About Us
News
Contact